TetraLogic Pharmaceuticals Corporation Announces Management Terminations; Authorizes the Implementation of a 19 Person Reduction in Staff
In connection with the reduction of the company's workforce, on January 20, 2016, the company notified Dr. G. Glenn Begley, the company's Chief Scientific Officer, and Dr. Lesley Russell, the company's Chief Operating Officer, of the termination of their employment to be effective April 19, 2016, in accordance with the notice requirements of their respective employment agreements with the company.